An interventional study of [18F]-GE-180 PET and 3T MRI in Ischemic Stroke, sponsored by Martin Dichgans. Recruiting at 2 sites in Germany. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.
Sponsored by Martin Dichgans · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 164 studies in Ischemic Stroke with a site in Germany — 41 open to participants now, 50 under way, 5 of them phase 3. Ischemic Stroke · Germany.
Among the 164 studies in Ischemic Stroke with a site in Germany, this one is the 89th largest by planned enrollment of the 101 interventional ones that give a count, is one of 7 that started in 2020, is one of 45 with no phase, reaches primary completion later than 19 of the 49 other live ones, and was the 105th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →41 of the 164 studies in Ischemic Stroke with a site in Germany are open now. Recruiting first, the newest first:
Ludwig-Maximilians - University of Munich · Sites in Germany
Ages 18+
Hospital Universitari Vall d'Hebron Research Institute · Sites in Germany, Belgium, Italy and 3 more countries
Ages 18+
Charite University, Berlin, Germany · Sites in Germany
Giuseppe Tarantini · Sites in Germany
Ages 18–65
Takeda · Sites in Germany, United States, Belgium and 7 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
164 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 33 · Phase 3 22 · Phase 4 4
First in 2000; this study’s year is marked. 7 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 223 across the 101 interventional studies, 410 across the 61 observational. Of the 98 that completed or were terminated, 25 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 164 have an industry lead sponsor. The 10 most frequent:
Martin Dichgans is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Martin Dichgans has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
14 of the studies in Ischemic Stroke with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT07357285iVascular S.L.U.Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO) | 2026-11 |
| NCT06121336Ludwig-Maximilians - University of MunichPRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke | 2026-12-31 |
| NCT07299994Sigmund Freud PrivatUniversitatEfficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease | 2026-12-31 |
| NCT04412187Martin DichgansInflammatory faCtors AfteR acUte Ischemic Stroke | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 164 studies in Ischemic Stroke with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ICARUS is an interventional single-centre hospital-based cohort study in patients admitted to the stroke unit with an acute ischemic stroke. The aims of the study are to i) define the characteristics and determinants of microglial activation after human stroke, and ii) assess the correlation of microglial activation with circulating inflammatory markers, structural brain changes on neuroimaging, and neurological outcomes.
ICARUS involves serial TSPO-PET imaging along with serial MRI, immune cell profiling in blood, and both clinical and laboratory assessments in 36 patients with acute ischemic stroke caused by a cortical (N=18) or strictly subcortical (N=18) infarct.
In a substudy, the investigators will include 10 independently recruited patients with acute ischemic stroke to assess MRI arterial spin labelling (ASL) sequences as a marker for perfusion measurement of the TSPO tracer.
The neuroinflammatory response after ischemic brain injury has been identified as a pathomechanism in ischemic stroke. Stroke induces an activation of microglia in the brain, which lasts over months. However, the characteristics and mechanisms of this microglia activation are insufficiently defined.
Our study hypotheses are (i) that a subpopulation of patients with acute stroke develop prominent microglial activation, and (ii) that patients with extensive microglial activation are more likely to experience poor outcome.
Against this background, the investigators set up the "Inflammatory faCtors AfteR acUte ischemic Stroke (ICARUS)" study as an interventional single-centre hospital-based cohort study. N=36 patients with a cortical (N=18) or strictly subcortical (N=18) acute ischemic stroke will be recruited through the local stroke unit (Department of Neurology, LMU Munich). Study participation involves serial TSPO-PET imaging along with serial MR imaging, immune cell profiling in blood, and both clinical and laboratory assessments. Follow-up assessments at 3 weeks, 3 months, 6 months and 12 months will be conducted at the Institute for Stroke and Dementia Research (ISD) and at the Department of Nuclear medicine, both LMU Munich.
In a substudy, the investigators will include 10 independently recruited patients with acute ischemic stroke to assess MRI arterial spin labelling (ASL) sequences as a marker for perfusion measurement of the TSPO tracer. These patients will receive dynamic PET in addition to the ASL sequences.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All study participants will receive \[18F\]-GE-180, i.e. TSPO PET imaging to assess microglia activation.
Diagnostic Test: [18F]-GE-180 PET · Diagnostic Test: 3T MRI · Diagnostic Test: immune cell profiling in blood
serial \[18F\]-GE-180 PET imaging to assess microglia activation
Also known as: TSPO PET imaging
serial MR imaging (i) to determine infarct characteristics, (ii) to identify gray and white matter structures connected to the infarct, (iii) to detect incident lesions, and (iv) to quantify longitudinal changes e.g. of cortical thickness
Cell-specific cytokine profiles, markers of activation, terminal differentiation as well as cytotoxicity will be assesses using flow cytometry.
microglia activation in patients with acute stroke
Microglia activation will be assessed using TSPO PET imgaing.
Time frame: within 10 days after acute ischemic stroke
microglia activation in patients with acute stroke
Microglia activation will be assessed using TSPO PET imgaing.
Time frame: 3 months after acute ischemic stroke
functional outcome in patients after acute ischemic stroke
Functional outcome measured by the modified Rankin Score (mRS) will be assessed and related to microglial activation.
Time frame: 3 weeks after acute ischemic stroke
functional outcome in patients after acute ischemic stroke
Functional outcome measured by the modified Rankin Score (mRS) will be assessed and related to microglial activation.
Time frame: 3 months after acute ischemic stroke
functional outcome in patients after acute ischemic stroke
Functional outcome measured by the modified Rankin Score (mRS) will be assessed and related to microglial activation.
Time frame: 6 months after acute ischemic stroke
functional outcome in patients after acute ischemic stroke
Functional outcome measured by the modified Rankin Score (mRS) will be assessed and related to microglial activation.
Time frame: 12 months after acute ischemic stroke
cognitive outcome in patients after acute ischemic stroke
Functional outcome in terms of cognition will be assessed by the Montreal Cognitive Assessment (MoCA) and related to microglial activation.
Time frame: 3 weeks after acute ischemic stroke
cognitive outcome in patients after acute ischemic stroke
Functional outcome in terms of cognition will be assessed by the Montreal Cognitive Assessment (MoCA) and related to microglial activation.
Time frame: 3 months after acute ischemic stroke
cognitive outcome in patients after acute ischemic stroke
Functional outcome in terms of cognition will be assessed by the Montreal Cognitive Assessment (MoCA) and related to microglial activation.
Time frame: 6 months after acute ischemic stroke
cognitive outcome in patients after acute ischemic stroke
Functional outcome in terms of cognition will be assessed by the Montreal Cognitive Assessment (MoCA) and related to microglial activation.
Time frame: 12 months after acute ischemic stroke
inflammatory markers in blood
Inflammatory markers in blood will be assessed by flow cytometry and related to microglial activation.
Time frame: 3 weeks after acute ischemic stroke
inflammatory markers in blood
Inflammatory markers in blood will be assessed by flow cytometry and related to microglial activation.
Time frame: 3 months after acute ischemic stroke
Duplex ultrasound
Duplex ultrasound will be performed to assess potential progress of atherosclerosis related to inflammatory markers
Time frame: 6 months after acute ischemic stroke
3T MR imaging
3T MRI will be performed to relate infarct evolution, secondary neurodegeneration, and stroke outcome to microglial activation.
Time frame: 3 months after acute ischemic stroke
3T MR imaging
3T MRI will be performed to relate infarct evolution, secondary neurodegeneration, and stroke outcome to microglial activation.
Time frame: 12 months after acute ischemic stroke
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2020 (actual). Primary completion is estimated for Dec 2026, 77 months after the start.
Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 77 months is above that.
Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Martin Dichgans